glp-1 agonists with cardiovascular benefit The effects of receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action The Cardiovascular Physiology of Glucagon-like
Description
Link Between GLP-1 Drugs and Thyroid Cancer There appears to be a slight increase in the incidence of thyroid cancer in GLP-1 users
Notably, delayed gastric emptying, a dose-dependent side effect, raises concerns of pulmonary aspiration during general anesthesia
In a monoiodoacetate (MIA) mouse model of OA inflammatory pain, injection of a GLP-1 analogue ameliorated pain sensitivity [85]
Pfizer completed a Phase 1 study for the drug in September and is still recruiting for another Phase 1 trial expected to run through April
Precision medicine for obesity
Combining GLP-1 receptor agonists with DPP-4 inhibitors is generally not recommended due to limited additive benefit
